Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2004 Jun 01;1423:485-94. doi: 10.1038/sj.bjp.0705795.
Show Gene links
Show Anatomy links
Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
Thomas D
,
Hammerling BC
,
Wu K
,
Wimmer AB
,
Ficker EK
,
Kirsch GE
,
Kochan MC
,
Wible BA
,
Scholz EP
,
Zitron E
,
Kathöfer S
,
Kreye VA
,
Katus HA
,
Schoels W
,
Karle CA
,
Kiehn J
.
???displayArticle.abstract???
1 The topoisomerase II inhibitor amsacrine is used in the treatment of acute myelogenous leukemia. Although most anticancer drugs are believed not to cause acquired long QT syndrome (LQTS), concerns have been raised by reports of QT interval prolongation, ventricular fibrillation and death associated with amsacrine treatment. Since blockade of cardiac human ether-a-go-go-related gene (HERG) potassium currents is an important cause of acquired LQTS, we investigated the acute effects of amsacrine on cloned HERG channels to determine the electrophysiological basis for its proarrhythmic potential. 2 HERG channels were heterologously expressed in human HEK 293 cells and Xenopus laevis oocytes, and the respective potassium currents were recorded using patch-clamp and two-microelectrode voltage-clamp electrophysiology. 3 Amsacrine blocked HERG currents in HEK 293 cells and Xenopus oocytes in a concentration-dependent manner, with IC50 values of 209.4 nm and 2.0 microm, respectively. 4 HERG channels were primarily blocked in the open and inactivated states, and no additional voltage dependence was observed. Amsacrine caused a negative shift in the voltage dependence of both activation (-7.6 mV) and inactivation (-7.6 mV). HERG current block by amsacrine was not frequency dependent. 5 The S6 domain mutations Y652A and F656A attenuated (Y652A) or abolished (F656A, Y652A/F656A) HERG current blockade, indicating that amsacrine binding requires a common drug receptor within the pore-S6 region. 6 In conclusion, these data demonstrate that the anticancer drug amsacrine is an antagonist of cloned HERG potassium channels, providing a molecular mechanism for the previously reported QTc interval prolongation during clinical administration of amsacrine.
Abbott,
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.
1999, Pubmed,
Xenbase
Abbott,
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.
1999,
Pubmed
,
Xenbase
Arnaout,
Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects.
2000,
Pubmed
Dhaliwal,
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
1986,
Pubmed
Griffin,
Amsacrine in refractory acute leukemia.
1985,
Pubmed
Hamill,
Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.
1981,
Pubmed
Jehn,
New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA.
1991,
Pubmed
Jurlina,
Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia.
1985,
Pubmed
Kantarjian,
New chemotherapeutic agents in acute myeloid leukemia.
1996,
Pubmed
Kiehn,
Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
1999,
Pubmed
,
Xenbase
Kuryshev,
Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.
2000,
Pubmed
Linssen,
Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L).
1993,
Pubmed
McLaughlin,
Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia.
1983,
Pubmed
Milnes,
Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
2003,
Pubmed
Mitcheson,
Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
2000,
Pubmed
,
Xenbase
Mitcheson,
A structural basis for drug-induced long QT syndrome.
2000,
Pubmed
,
Xenbase
Mitcheson,
Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine.
2003,
Pubmed
Napolitano,
Torsade de pointes. Mechanisms and management.
1994,
Pubmed
Paxton,
The binding of amsacrine to human plasma proteins.
1986,
Pubmed
Redfern,
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
2003,
Pubmed
Rowe,
Treatment of acute myelogenous leukemia in older adults.
2000,
Pubmed
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Sanguinetti,
Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
1990,
Pubmed
Scholz,
Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
2003,
Pubmed
,
Xenbase
Schwartz,
QT interval prolongation and cardiac dysrhythmia in a patient receiving amsacrine.
1984,
Pubmed
Seymour,
Induction of hypomagnesemia during Amsacrine treatment.
1993,
Pubmed
Shinar,
Acute electrocardiographic changes induced by amsacrine.
1984,
Pubmed
Teschemacher,
Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.
1999,
Pubmed
Thomas,
The antipsychotic drug chlorpromazine inhibits HERG potassium channels.
2003,
Pubmed
,
Xenbase
Thomas,
Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen.
2003,
Pubmed
,
Xenbase
Thomas,
High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
2001,
Pubmed
,
Xenbase
Viskin,
Long QT syndromes and torsade de pointes.
1999,
Pubmed
Von Hoff,
Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).
1980,
Pubmed
Warmke,
A family of potassium channel genes related to eag in Drosophila and mammals.
1994,
Pubmed
Weerapura,
A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?
2002,
Pubmed
,
Xenbase
Weiss,
Amsacrine-associated cardiotoxicity: an analysis of 82 cases.
1986,
Pubmed
Winton,
Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
1985,
Pubmed
